Zobrazeno 1 - 10
of 737
pro vyhledávání: '"Richard M Goldberg"'
Autor:
Fang-Shu Ou, Emil Lou, Joanne Xiu, Hiroyuki Arai, Francesca Battaglin, Heinz-Josef Lenz, Richard M Goldberg, Anthony F Shields, Yasmine Baca, Philip A Philip, John L Marshall, W Michael Korn, Andreas Seeber, Natsuko Kawanishi, Jingyuan Wang, Shivani Soni, Wu Zhang, Shannon M Mumenthaler, Joshua Millstein, Priya Jayachandran, Federico Innocenti, Annika Lenz, Sandra Algaze, Taline Khoukaz, Evanthia Roussos Torres, Jim P Abraham, Benjamin A Weinberg, Alan P Venook
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background The C-C motif chemokine receptor 5 (CCR5)/C-C motif chemokine ligand 5 (CCL5) axis plays a major role in colorectal cancer (CRC). We aimed to characterize the molecular features associated with CCR5/CCL5 expression in CRC and to determine
Externí odkaz:
https://doaj.org/article/0070d43d733f41d1a13e1ef74847bb8d
Autor:
Michael Hall, Arno Amann, Joanne Xiu, Alberto Puccini, Francesca Battaglin, Heinz-Josef Lenz, Mohamed E Salem, Gilbert Spizzo, Richard M Goldberg, Axel Grothey, Anthony F Shields, Sukeshi Patel Arora, Yasmine Baca, Wafik S El-Deiry, Philip A Philip, Madiha Nassem, John L Marshall, Florian Kocher, Dominik Wolf, W Michael Korn, Andreas Seeber, Moh’d Khushman
Publikováno v:
ESMO Open, Vol 5, Iss 3 (2020)
Introduction Prognosis of biliary tract cancers (BTC) remains dismal and novel treatment strategies are needed to improve survival. BRCA mutations are known to occur in BTC but their frequency and the molecular landscape in which they are observed in
Externí odkaz:
https://doaj.org/article/5711ba0e941d44f399ba02ac4f8a8c3c
Autor:
Hanna K Sanoff, Lindsay A Renfro, Pradeep Poonnen, Pratibha Ambadwar, Daniel J Sargent, Richard M Goldberg, Howard McLeod
Publikováno v:
PLoS ONE, Vol 9, Iss 4, p e94727 (2014)
Colorectal cancer (CRC) risk is partly conferred by common, low-penetrance single nucleotide polymorphisms (SNPs). We hypothesized that these SNPs are associated with outcomes in metastatic CRC.Six candidate SNPs from 8q24, 10p14, 15q13, 18q21 were i
Externí odkaz:
https://doaj.org/article/edd25e9487834610ba60cc4912fd4d3e
Autor:
Thomas Pavelitz, Lindsay Renfro, Nathan R Foster, Amber Caracol, Piri Welsch, Victoria Valinluck Lao, William B Grady, Donna Niedzwiecki, Leonard B Saltz, Monica M Bertagnolli, Richard M Goldberg, Peter S Rabinovitch, Mary Emond, Raymond J Monnat, Nancy Maizels
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e108483 (2014)
PURPOSE:Colon cancers deficient in mismatch repair (MMR) may exhibit diminished expression of the DNA repair gene, MRE11, as a consequence of contraction of a T11 mononucleotide tract. This study investigated MRE11 status and its association with pro
Externí odkaz:
https://doaj.org/article/12fbd8e82c5d447bb904205e39b02664
Autor:
Claire Gallois, Qian Shi, Jeffrey P. Meyers, Timothy Iveson, Steven R. Alberts, Aimery de Gramont, Alberto F. Sobrero, Daniel G. Haller, Eiji Oki, Anthony Frank Shields, Richard M. Goldberg, Rachel Kerr, Sara Lonardi, Greg Yothers, Caroline Kelly, Ioannis Boukovinas, Roberto Labianca, Frank A. Sinicrope, Ioannis Souglakos, Takayuki Yoshino, Jeffrey A. Meyerhardt, Thierry André, Demetris Papamichael, Julien Taieb
Publikováno v:
Journal of Clinical Oncology. 41:803-815
PURPOSE Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to whether early discontinuation of all treatment (ETD) or early discont
Autor:
Jan Franko, Jun Yin, Richard A. Adams, John Zalcberg, Jack Fiskum, Eric Van Cutsem, Richard M. Goldberg, Herbert Hurwitz, Carsten Bokemeyer, Fairooz Kabbinavar, Alexandra Curtis, Jeffery Meyers, Benoist Chibaudel, Takayuki Yoshino, Aimery de Gramont, Qian Shi
Publikováno v:
European Journal of Cancer. 174:142-152
Higher body mass index is associated with a higher incidence of colorectal cancer (CRC) but also with improved survival in metastatic CRC (mCRC). Whether weight change after mCRC diagnosis is associated with survival remains largely unknown.We analys
Autor:
Nadine J. McCleary, Sui Zhang, Chao Ma, Fang-Shu Ou, Tiffany M. Bainter, Alan P. Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Bert H. O'Neil, Blase N. Polite, Howard S. Hochster, James N. Atkins, Richard M. Goldberg, Kimmie Ng, Robert J. Mayer, Charles D. Blanke, Eileen M. O'Reilly, Charles S. Fuchs, Jeffrey A. Meyerhardt
Publikováno v:
J Geriatr Oncol
BACKGROUND: Little is known about the interaction of comorbidities and age on survival outcomes in colorectal ancer (mCRC), nor how comorbidities impact treatment tolerance. METHODS: We utilized a cohort of 1,345 mCRC patients enrolled in CALGB/SWOG
Autor:
Al B. Benson, Sharyn Worrall, Keavy McAbee, Anjelica Q. Davis, Nancy Roach, Jill O'Donnell-Tormey, Edward Cha, Rebecca A. Moss, Arvin Yang, Neil H. Segal, Cynthia L. Sears, Wells Messersmith, Christopher H. Lieu, Smitha S. Krishnamurthi, S. Peter Kang, Elizabeth M. Jaffee, Franck Housseau, Stanley R. Hamilton, Richard M. Goldberg, Wolf H. Fridman, Luis A. Diaz, Dustin A. Deming, Emily Chan, Arthur N. Brodsky, Thomas H. Marsilje, Andrea Dwyer, Christopher R. Heery, Michael A. Morse, Vanessa M. Hubbard-Lucey, Dung T. Le
Immunotherapy is rapidly becoming a standard of care for many cancers. However, colorectal cancer had been generally resistant to immunotherapy, despite features in common with sensitive tumors. Observations of substantial clinical activity for check
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fe819a9579ba657dff6e159f30b6a62
https://doi.org/10.1158/2326-6066.c.6548287.v1
https://doi.org/10.1158/2326-6066.c.6548287.v1
Autor:
Al B. Benson, Sharyn Worrall, Keavy McAbee, Anjelica Q. Davis, Nancy Roach, Jill O'Donnell-Tormey, Edward Cha, Rebecca A. Moss, Arvin Yang, Neil H. Segal, Cynthia L. Sears, Wells Messersmith, Christopher H. Lieu, Smitha S. Krishnamurthi, S. Peter Kang, Elizabeth M. Jaffee, Franck Housseau, Stanley R. Hamilton, Richard M. Goldberg, Wolf H. Fridman, Luis A. Diaz, Dustin A. Deming, Emily Chan, Arthur N. Brodsky, Thomas H. Marsilje, Andrea Dwyer, Christopher R. Heery, Michael A. Morse, Vanessa M. Hubbard-Lucey, Dung T. Le
Supplemental Tables 1 and 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::707eae64e6122a01edf458348b5685d3
https://doi.org/10.1158/2326-6066.22536955.v1
https://doi.org/10.1158/2326-6066.22536955.v1
Autor:
Andrew B. Nixon, Federico Innocenti, Hanna K. Sanoff, Michael S. Lee, Dominic T. Moore, Anastasia Ivanova, Kouros Owzar, Chiara Cremolini, Alfredo Falcone, Richard M. Goldberg, Daniele Rossini, Federica Marmorino, Kelli Hammond, John C. Brady, Mark D. Starr, Ace J. Hatch, Alexander B. Sibley, Kirsten Bell Burdett, Jing Lyu, Yingmiao Liu
Regorafenib is a tyrosine kinase inhibitor approved by the FDA for the treatment of patients with chemotherapy refractory metastatic colorectal cancer (mCRC). Regorafenib inhibits signaling through multiple receptors associated with angiogenesis, met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cc13a6f6766962d7be65cf3e676a3ff
https://doi.org/10.1158/1535-7163.c.6542764
https://doi.org/10.1158/1535-7163.c.6542764